ArticleFrontiers in cellular and infection microbiology2026
Clinical epidemiology and viral genomics insights from a Chikungunya fever outbreak in South China, 2025.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Research advances in chikungunya virus: Epidemiology, pathogenesis, and control.One health (Amsterdam, Netherlands) · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chikungunya fever (CHIKF) is a mosquito-borne viral disease characterized by fever, rash, and severe joint pain. However, these classical descriptions are based overwhelmingly on the Indian Ocean and Caribbean lineages. With the recent introduction and spread of the Middle Africa lineage (MAL) into Asia, understanding its clinical presentation in new populations, such as Chinese, has become a public health priority. Whether the recently introduced MAL causes comparably severe disease in China remains unknown. Methods: We enrolled 415 laboratory-confirmed cases of Chikungunya virus (CHIKV) infection during an outbreak in Foshan, China. Clinical manifestations, laboratory parameters, and whole-genome sequencing data were integrated to quantify the symptom burden from three different perspectives using multivariate logistic regression, and to trace the viral source via maximum-likelihood phylogenetic analysis. Results: Compared with the classical phenotype, the MAL outbreak in China was appreciably milder. The most common clinical manifestations were arthralgia (83.61%), fever (74.46%), and rash (61.93%). Multivariate logistic regression showed that older age (OR = 0.979, P = 0.029) and male sex (OR = 0.528, P = 0.038) were negatively correlated with the occurrence of higher symptom burden, while prolonged fever (OR = 8.156, P < 0.001) was a significant risk factor. Reduced estimated glomerular filtration rate and thrombocytopenia were associated with longer disease duration. Phylogenetic analysis revealed that the outbreak-associated CHIKV strains belonged to MAL and harbored the E1-A226V and E2-I211T mutations. Conclusion: These findings provide an evidence base for clinical management and prognostic assessment during CHIKF outbreaks and underscore the importance of monitoring laboratory parameters alongside molecular surveillance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.